Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.

Nonalcoholic fatty liver disease ups risk of death

13 Aug 2019

Nonalcoholic fatty liver disease (NAFLD) heightens the risk of all-cause death but not from cardiovascular diseases (CVD) or cancer, reports a recent meta-analysis.

Accessing the databases of PubMed and Embase, researchers retrieved 14 studies that investigated the effect of NAFLD on mortality risk. Reports that used NAFLD patients as the reference group or assessed mortality in patients undergoing bariatric surgery or liver transplantation were ineligible. The Newcastle-Ottawa scale was used to evaluate methodological quality.

A total of 24,188 deaths were reported in the cumulative sample of 498,259 participants. Pooled analysis revealed a significantly higher death risk in NAFLD patients (hazard ratio [HR], 1.34, 95 percent CI 1.17–1.54), though the evidence had substantial heterogeneity (p<0.01).

Subsequent subgroup analyses found that NAFLD was a significant mortality hazard in women (four studies; HR, 1.49, 1.15–1.93) but not in men (four studies, HR, 1.08, 0.83–1.41). In contrast, there were no meaningful effect modifications according to age, sex, NAFLD severity, the presence of fibrosis or cirrhosis, follow-up duration, comorbidities, and the method used to diagnose NAFLD.

The effect of NAFLD on death risk appeared to be robust, as excluding four studies with large sample sizes did not change the principal findings. NAFLD also exerted a similar effect on the likelihood of death from liver disease (HR, 2.53, 1.23–5.18).

On the other hand, NAFLD had no apparent effect on the risk of death from CVDs (HR, 1.13, 0.92–1.38) and cancer (HR, 1.05, 0.89–1.25).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.